ArticleJournal of the Canadian Association of Gastroenterology2020
The Impact of Transitioning From Guaiac-Fecal Occult Blood Testing to Fecal Immunochemical Testing in a Canadian Colon Cancer Screening Program.
Article in Journal of the Canadian Association of Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Physician payment models and preventive cancer screening: a population-based retrospective cohort analysis from Ontario, Canada.Family practice · 2025Article
- Enhancing CRC Screening in a Predominantly Hispanic Community: Effectiveness of 1-Day vs. 3-Day Stool-Based Testing Kits.Journal of community health · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the impact of transitioning from guaiac-based fecal occult blood testing (gFOBT) to fecal immunochemical testing (FIT) on the detection rate of adenomas, advanced adenomas (AA) and colorectal cancer (CRC).
backgroundRecently, the health region in Edmonton, Alberta switched from gFOBT to FIT for CRC screening. STUDY: A retrospective analysis of all patients, aged 50 to 74 years, referred for colonoscopy from January 1, 2013 to December 31, 2014 due to a positive gFOBT (at least one of three samples positively using the guaiac-based Hemoccult II SENSA in 2013) or FIT (≥75 µg/g of stool, using the Polymedco OC FIT-CHEK in 2014). The primary outcomes were the number of colon cancers, AA and adenomas detected in 2013 and 2014. A comparison between the two tests was also made for the composite outcome of detection of either AA or CRC.
resultsSix hundred and forty-nine patients underwent colonoscopy due to a positive gFOBT in 2013, and 2167 patients for a positive FIT in 2014. FIT compared with gFOBT detected more CRC (67 compared with 34), AA (770 compared with 147) and adenomas (1575 versus 320). By multivariable regression analysis adjusted for different demographics and endoscopic metrics, positive FIT was independently associated with higher adenoma detection rate (odds ratio [OR] 2.62; 95% confidence interval [CI] 2.13 to 3.21,
conclusionsAdoption of FIT compared with gFOBT led to higher detection of colon cancer, AA and adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.